Compare DYN & LION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DYN | LION |
|---|---|---|
| Founded | 1984 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2020 | N/A |
| Metric | DYN | LION |
|---|---|---|
| Price | $16.60 | $9.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $39.94 | $9.89 |
| AVG Volume (30 Days) | 2.1M | ★ 2.4M |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,954,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 39.38 |
| 52 Week Low | $6.36 | $5.55 |
| 52 Week High | $25.00 | $10.09 |
| Indicator | DYN | LION |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 49.12 |
| Support Level | $16.10 | $8.74 |
| Resistance Level | $17.45 | $9.36 |
| Average True Range (ATR) | 1.01 | 0.42 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 15.50 | 22.96 |
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.